Carregant...
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
Most pituitary adenomas (PAs) are considered benign tumors, but approximately 0.2% can present metastasis and are classified as pituitary carcinomas (PCs). Refractory PAs lie between benign adenomas and true malignant PC and are defined as aggressive-invasive PAs characterized by a high Ki-67 index,...
Guardat en:
| Publicat a: | Front Endocrinol (Lausanne) |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7761748/ https://ncbi.nlm.nih.gov/pubmed/33362722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2020.608422 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|